A new batch of anti-cancer drugs is exempted from value-added tax.

In order to encourage the development of the pharmaceutical industry and reduce the cost of drug use for patients, from this month, a number of anti-cancer drugs and rare disease drugs to implement the relevant value-added tax policy.
The Ministry of Finance, the General Administration of Customs, the General Administration of Taxation and the Drug Administration have issued a new batch of anti-cancer drugs and rare diseases as of October 1, 2020, according to the Ministry of Finance, General Administration of Customs, General Administration of Taxation, State Drug Administration on anti-cancer drugs Notice of VAT Policy (Finance and Taxation (2018) No. 47), Notice of the General Administration of Taxation of the Ministry of Finance, General Administration of Taxation, Notice of the Drug Administration on VAT Policy on Rare Disease Drugs (No. 24 of Fiscal and Taxation (2019)) provides for the implementation of the relevant VAT policy.
the above-mentioned relevant policies, as of March 1, 2019, VAT general taxpayers who produce, sell and wholesale and retail rare disease drugs may choose to pay VAT at a simple rate of 3%.
shall not be changed for 36 months after the above-mentioned taxpayers choose the simple method to calculate the payment of value-added tax.
1 March 2019, the import of rare disease drugs will be reduced by 3% of the import value-added tax.
Beijing Youth Daily reporter learned that the reduction of value-added tax drugs, including non-small cell lung cancer targeted treatment drug dacotinib tablets, metastatic colorectal cancer treatment drug pyridinib capsules and other 45 anti-cancer drug preparations and raw materials, as well as the treatment of multiple sclerosis of Teflon tablets, treatment of spinal myotrophic sodium injections and other 14 rare disease drugs.
(Reporter Zhang Qin)